Evidence map›Paper›PMID 41655694›Full record

ArticleThe Journal of biological chemistry2026

Cytomegalovirus-encoded immediate early 1 protein perturbs neural progenitor proliferation via interfering with host PML-DISC1 interaction.

Atsushi Saito, Stephanie Tankou, Kazuhiro Ishii, Makiko Sakao-Suzuki, Edwin C Oh, Hannah Murdoch, Ho Namkung, Sunday Adelakun, Keiko Furukori, Masahiro Fujimuro and 12 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Atsushi SaitoDepartment of Neuroscience, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA; Department of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Stephanie TankouDepartment of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Kazuhiro IshiiDepartment of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Makiko Sakao-SuzukiDepartment of Regenerative & Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Edwin C OhNevada Institute of Personalized Medicine, University of Nevada, Las Vegas, Nevada, USA.
Hannah MurdochMolecular Pharmacology Group, Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK.
Ho NamkungDepartment of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Sunday AdelakunDepartment of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Keiko FurukoriDepartment of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Masahiro FujimuroDepartment of Cell Biology, Kyoto Pharmaceutical University, Kyoto, Japan.
Paolo SalomoniNuclear Function in CNS Pathophysiology, German Center for Neurodegenerative Diseases, Bonn, Germany.
Gerd G MaulThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Gary S HaywardDepartment of Oncology, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Qiyi TangDepartment of Microbiology, Howard University College of Medicine, Washington, District of Columbia, USA.
Robert H YolkenDepartment of Pediatrics, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Miles D HouslayInstitute of Pharmaceutical Science, King's College London, London, UK.
Nicholas KatsanisRescindo Therapeutics Inc, Cary, North Carolina, USA.
Isao KosugiDepartment of Regenerative & Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kun YangDepartment of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Atsushi KamiyaDepartment of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Koko IshizukaDepartment of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA.
Akira SawaDepartment of Neuroscience, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA; Department of Psychiatry, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA; Department of Genetic Medicine, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA; Department of Mental Health, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, USA. Electronic address: asawa1@jhmi.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital cytomegalovirus (CMV) infection is the most common perinatal infection, affecting up to 0.5% of infants. This elicits long-term disabilities that include neuropsychiatric manifestations, such as intellectual disability, microcephaly. Despite its high prevalence, the underlying mechanism of how congenitally acquired CMV infection causes brain pathology remain unknown. Here, we discovered the molecular interplay of key host (DISC1 and promyelocytic leukemia [PML]) and viral (immediate early 1 [IE1]) proteins within the neural progenitor cells, which underlay an attenuated neural progenitor proliferation in congenital CMV infection. Abolishing the viral IE1 protein by delivering IE1-targeting CRISPR/Cas9 to fetal brain rescued this progenitor cell deficit, a key pathology in congenital CMV infection. A selective targeting to a viral-specific protein by the CRISPR/Cas9 system is minimal in off-target effects. We further observed that CMV-encoded IE1 protein interferes with host PML-DISC1 interaction, resulting in disturbance of the Notch pathway in vitro and in embryonic brains. Therefore, we believe that a pivotal role of IE1 in an attenuated neural progenitor proliferation in the developing cortex through its interfering with interaction between host DISC1 and PML proteins.

Indexed as

CytomegalovirusImmediate-Early ProteinsNerve Tissue ProteinsNeural Stem CellsPromyelocytic Leukemia ProteinAnimalsCell ProliferationHumansDISC1 protein, humanIE1 protein, cytomegalovirusImmediate-Early ProteinsNerve Tissue ProteinsPML protein, humanPromyelocytic Leukemia Proteinbraincongenital infectionCRISPR/CascytomegalovirusDISC1neural progenitorneurodevelopmentPMLvirus

Identifiers

PMID41655694
PMCPMC12992096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.